<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">In contrast, others have not ruled out HCTs on emerging infectious diseases and noted that the way risks should be calculated in the context of an ongoing outbreak might be relevant. Joffe and Miller argue that:
 <disp-quote>
  <p id="Par24">[V] olunteers for high-risk public-health research may be subject to substantial background risk from public-health threats, such as potentially lethal infectious diseases for which effective treatment is lacking. It is thus the incremental net risk from the research that must be assessed against the prospect of public-health benefits from the study results [
   <xref ref-type="bibr" rid="CR6">6</xref>].
  </p>
 </disp-quote>
</p>
